| Size | Price | |
|---|---|---|
| 5mg | ||
| 10mg | ||
| Other Sizes |
| ln Vitro |
With all D-amino acids, P8RI (D-P8RI) was created as a retro-inverse peptide that preserves biological activity and offers resistance against plasma proteases [1].
|
|---|---|
| ln Vivo |
In accordance with the enrichment of M2 macrophages at this region, P8RI (2.5 mg/kg; subcutaneous injection; 7 to 28 days after ADIM) inhibits aneurysmal transformation by encouraging the clearance of intramural hematoma and collagen creation in the dissected aorta in vivo. connected to collections[3].
|
| Animal Protocol |
Animal/Disease Models: Apo E -/- mice (male, 28weeks old) implanted with Ang II-releasing pumps (a model of experimental acute aortic dissection and intramural hematoma (ADIM))[3]
Doses: 2.5 mg/kg Route of Administration: subcutaneous (sc) injection; daily from 7 to 28 (after the implantation of the osmotic pump delivering Ang II) Experimental Results: Aneurysmal transformation was Dramatically decreased. |
| References |
| Molecular Formula |
C51H77N13O9
|
|---|---|
| Molecular Weight |
1016.24
|
| Exact Mass |
1015.596
|
| CAS # |
2147724-76-1
|
| PubChem CID |
162678845
|
| Appearance |
White to off-white solid powder
|
| LogP |
-0.7
|
| Hydrogen Bond Donor Count |
12
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
29
|
| Heavy Atom Count |
73
|
| Complexity |
1880
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
C(C1=CNC2=CC=CC=C12)[C@@H](NC(=O)[C@H](N)CCCCN)C(N1CCC[C@@H]1C(=O)N[C@H](C)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](C(=O)N[C@H](C(C)C)C(=O)N[C@@H](C(=O)O)CCCNC(N)=N)CC1C=CC=CC=1)=O
|
| InChi Key |
LXYOOXZYRDPHLW-PJJIIYKISA-N
|
| InChi Code |
InChI=1S/C51H77N13O9/c1-29(2)25-38(45(67)61-39(26-32-15-7-6-8-16-32)46(68)63-42(30(3)4)48(70)59-37(50(72)73)20-13-23-56-51(54)55)60-43(65)31(5)58-47(69)41-21-14-24-64(41)49(71)40(62-44(66)35(53)18-11-12-22-52)27-33-28-57-36-19-10-9-17-34(33)36/h6-10,15-17,19,28-31,35,37-42,57H,11-14,18,20-27,52-53H2,1-5H3,(H,58,69)(H,59,70)(H,60,65)(H,61,67)(H,62,66)(H,63,68)(H,72,73)(H4,54,55,56)/t31-,35-,37-,38-,39-,40-,41-,42-/m1/s1
|
| Chemical Name |
(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-1-[(2R)-2-[[(2R)-2,6-diaminohexanoyl]amino]-3-(1H-indol-3-yl)propanoyl]pyrrolidine-2-carbonyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: 100 mg/mL (98.40 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (98.40 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.9840 mL | 4.9201 mL | 9.8402 mL | |
| 5 mM | 0.1968 mL | 0.9840 mL | 1.9680 mL | |
| 10 mM | 0.0984 mL | 0.4920 mL | 0.9840 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
